IDEXX Laboratories, Inc.
Financials
Valuation Metrics
IDEXX Laboratories, Inc.'s Market Cap is $44.79B. At end of 2025 it was $54.19B. Ranked #352 of 3,111 in US market (top 11%), #98 of 1,445 on NASDAQ (top 7%), #18 of 206 in Health Care Equipment & Services (top 9%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $44.79B | US#352/3,111 Sec#18/206 |
| Revenue | $4.45B | US#971/3,111 Sec#52/206 |
| Net Income | $1.10B | US#488/3,111 Sec#26/206 |
| Total Assets | $3.39B | US#1,722/3,111 Sec#80/206 |
| Net Assets | $1.56B | US#1,449/3,111 Sec#74/206 |
| Employees | 11,000 | US#563/3,111 Sec#52/206 |
| Value | ||
| P/E | 40.90x | US#1,718/3,111 Sec#78/206 |
| P/B | 28.79x | US#2,880/3,111 Sec#193/206 |
| PEG | 2.77x | US#1,112/3,111 Sec#55/206 |
| P/S | 10.07x | US#2,657/3,111 Sec#187/206 |
| EV/EBITDA | 29.32x | US#2,160/3,111 Sec#112/206 |
| FCF Yield | 2.41% | US#1,871/3,111 Sec#116/206 |
| Profitability | ||
| ROE | 70.38% | US#67/3,111 Sec#5/206 |
| ROA | 32.35% | US#22/3,111 Sec#1/206 |
| Op. Margin | 31.63% | US#393/3,111 Sec#9/206 |
| Revenue Growth | 14.26% | US#1,010/3,111 Sec#69/206 |
| Earnings Growth | 14.74% | US#1,029/3,111 Sec#49/206 |
| Financial Health | ||
| Debt Ratio | 117.56% | US#1,240/3,111 Sec#119/206 |
| Total Debt | $1.11B | US#1,455/3,111 Sec#76/206 |
| FCF | $1.08B | US#537/3,111 Sec#36/206 |
| Cash | $201M | US#1,730/3,111 Sec#100/206 |
| Current Ratio | 1.12x | US#2,129/3,111 Sec#184/206 |
| Net Debt/EBITDA | 0.58x | US#842/3,111 Sec#50/206 |
| Performance | ||
| 1Y Return | 6.03% | US#1,880/3,111 Sec#124/206 |
| 1M Return | 1.80% | US#988/3,111 Sec#81/206 |
| From 52W High | -26.25% | US#2,005/3,111 Sec#136/206 |
| 1Y MDD | -31.34% | US#1,478/3,111 Sec#59/206 |
| Trading | ||
| Volume | 1,047,992 shares | US#1,993/3,111 Sec#133/206 |
| Trading Value | $597M | US#356/3,111 Sec#23/206 |
| Per Share | ||
| EPS | $13.23 | US#157/3,111 Sec#13/206 |
| BPS | $20.04 | US#1,206/3,111 Sec#69/206 |
Company Info
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.